Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest
FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.
You may also be interested in...
Several senators have joined the chorus of health care providers mystified by the way the Trump administration is doling out Gilead’s investigational antiviral from the federal stockpile for COVID-19 patients.
AmerisourceBergen, McKesson, Cardinal and others can help FEMA deliver hydroxychloroquine and manage critical-drugs supply chain without running afoul of federal antitrust law.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.